Browse > Home / Markets, Strategy / Amgen (AMGN) – CEO Comments and Lowering Guidance

Amgen (AMGN) – CEO Comments and Lowering Guidance

January 12, 2010 2:02 pm

Amgen was put up one of the best ideas for 2010 by Blackrock’s Bob Dole this morning. At the same time, we seeing the following notes from the recent JP Morgan Healthcare Conference regarding Amgen (AMGN):

  • Amgen Plans To Remain Active In Acquisitions, Licensing
  • Amgen Ceo Sharer Says 2009 Eps Slightly Below Midpoint Forecast
  • Amgen Ceo Believes Healthcare Bill Will Pass, Says Ceo Makes Remarks At JP Morgan Healthcare Conference
  • Amgen Will See More Biosimilar Competition In Europe, Ceo Says

In addition, Amgen (AMGN) sees 2009 at low end of view of EPS USD 4.90 – USD 4.95

Our biggest concern for the company has been the development of the bio-similar competition from several companies including Teva (TEVA). Even though the proposed health care bill (in its latest form) appears to push the creation of  “generic” version of Amgen’s drugs further into the future, it is far from a done deal.

On a technical basis there is plenty of reasons to look at Amgen as a short candidate as well. The general trend down over the past year and volume has been considerably higher on the days the shares sell-off. In addition we have seen several long legged candles which have generally been bullish reversals

These reversals are coming as shares hit support at the $55 level. If support is broken, we see that a 4-6% fall could be seen quickly. Shares are in a tight range between $54 – $58.

Finally, we see the slow stochastics as a good confirmation of the shorter term trend and continue to short shares in our portfolios until we see a clear break of resistance.

___
Disclosure: Horowitz & Company clients may hold positions of securities mentioned as of the date published.

Be Sociable, Share!

Sorry, No Related Posts.

Disclosure: This material is provided for information only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. This material is not a complete analysis of all material facts respecting any issuer, industry or security or of your investment objectives, parameters, needs or financial situation, and therefore is not a sufficient basis alone on which to base an investment decision. Horowitz & Company clients may hold positions (long or short) in investments discussed.
Please click for detailed disclosures and additional information about our stock ratings and scoring.

Written by Andrew Horowitz · Category(s) Markets, Strategy    |  Tags: • •   

2 Responses to “Amgen (AMGN) – CEO Comments and Lowering Guidance”

  1. prosfores on October 21st, 2011 3:41 pm

    Hello there, simply changed into aware of your blog through Google, and found that it is truly informative. I am gonna watch out for brussels. I will be grateful in the event you proceed this in future. A lot of folks might be benefited out of your writing. Cheers!

  2. Frankie Litchard on December 7th, 2011 5:28 pm

    Accidentally go through your post. I’ve found it truly is unique. Good posting and expect the next information.

Got something to say?